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Objective: This study aimed to characterize the differences in protein oxidation biomarkers in adipose  
tissue (AT) as an indicator of AT metabolism and bariatric surgery weight-loss success.
Methods: A human model, in which sixty-five individuals with obesity underwent bariatric surgery, and a 
diet-induced obesity animal model, in which animals were treated for 2 months with normocaloric diets, 
were analyzed to determine the associations between AT protein oxidation and body weight loss. Protein 
oxidative biomarkers were determined by gas chromatography/mass spectrometry in AT from human  
volunteers before the surgery, as well as 2 months after a diet treatment in the animal model.
Results: The levels of carboxyethyl-lysine (CEL) and 2-succinocystein (2SC) in both visceral and subcutane-
ous AT before the surgery directly correlated with greater weight loss in both human and animal models. 2SC 
levels in subcutaneous AT greater than 4.7 × 106 μmol/mol lysine (95% CI: 3.4 × 106 to 6.0 × 106) may predict 
greater weight loss after bariatric surgery (receiver operating characteristic curve area = 0.8222; P = 0.0047). 
Additionally, it was observed that individuals with diabetes presented lower levels of CEL and 2SC in subcu-
taneous AT (P = 0.0266 and P = 0.0316, respectively) compared with individuals without diabetes.
Conclusions: CEL and 2SC in AT are useful biomarkers of AT metabolism and predict the individual’s ability 
to reduce body weight after bariatric surgery.
Obesity (2019) 27, 1133-1140. doi:10.1002/oby.22501
Introduction
The use of bariatric surgery as an intervention for inducing weight 
loss among patients with morbid obesity has been clearly demonstrated 
to be the most effective in terms of time and body weight reduction. 
In a meta-analysis that included 11 studies, bariatric surgery induced 
greater weight loss (mean difference of −26  kg at 1- to 3-year 
follow-up) compared with nonsurgical treatment (1). However, 20% to 
25% of the individuals operated on have had inadequate response (2). 
It has been suggested that the effectiveness of weight-loss reduction 
depends largely on some preoperative factors such as the age of onset 
of obesity, high preoperative BMI, diabetes, and hypertension; all 
have been associated with unsuccessful weight loss (3,4). To identify 
these individuals is a challenge, both for the physician and for health 
administrations.
Greater visceral adipose tissue (VAT) to subcutaneous adipose tissue 
(SAT) ratio, which has been associated with nonremission of diabetes, 
was shown to be a predictive parameter of poor outcome following bar-
iatric surgery (5). The basis for the proposed harmful effect of VAT, in 
particular, is due to the draining of portal blood to the liver, affecting 
its glucose metabolism and thus whole-body glucose homeostasis, 
possibly via the secretion of adipokines. Furthermore, increased 
intra-abdominal fat has been associated with an adverse metabolic 
profile and has been found to predict the development of obesity-related 
diseases (6). However, the deleterious role of VAT per se in obesity 
pathophysiology is still far from clear. For example, from a metabolic 
point of view, VAT (per milligram of tissue) was shown to be more meta-
bolically active than SAT and to have twice the number of mitochondria 
as SAT (7). In the same sense, in healthy individuals with obesity, 
adipose tissue perfusion and insulin-stimulated glucose uptake per gram 
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of tissue were found to be significantly higher in VAT compared with 
SAT (8). Moreover, the ratio of VAT to SAT after bariatric surgery was 
shown to remain fairly constant regardless of the presence of metabolic 
syndrome or the loss of body weight (9). In the case of patients with type 
2 diabetes, they lost less weight and visceral fat after bariatric surgery 
but more muscle mass compared with their nondiabetic counterparts (10).
Few studies have measured glucose oxidative bioenergetic function of 
adipocytes and its potential relationship with treatment success during 
weight-reduction programs. Adipocytes are a major site of lactate pro-
duction (11), a process stimulated by insulin and glucose uptake, the 
inadequate release of which was altered in the adipose tissue of women 
with insulin resistance and obesity (12). Therefore, an adequate adi-
pose tissue glucose metabolism and its consequent lactate production 
are proxies for the change in metabolic flux during the transition from 
the fasted to the fed state (13). Notwithstanding, it is not clear whether 
the increased glycolytic activity in adipose tissue induced by high blood 
levels of glucose and insulin, and the consequent generation of oxida-
tion by-products, may influence its metabolic capacity. The aim of this 
study was to explain differences in weight loss through the characteri-
zation of protein oxidation biomarkers as a measure of glycolytic flux 
in adipose tissue of patients with morbid obesity undergoing bariatric 
surgery as well as in an animal model of obesity before and after dietary 
energy-restriction treatment.
Methods
Participants
A total of 65 consecutive patients of Caucasian origin who under-
went bariatric surgery between July 2013 and September 2014 were 
enrolled at the time of a regular visit to the outpatient obesity unit. In 
line with previous studies (2), sample size was calculated by assum-
ing that 25% of bariatric surgery patients may have an inadequate 
response to the surgery. A precision of 10% and a confidence level of 
95% were established for sample size calculation. Written informed 
consent was obtained from all participants, and the human ethics 
committee of the Arnau de Vilanova University Hospital approved 
the study (CEIC 1176). The study was conducted according to the 
ethical guidelines of the Helsinki Declaration. The following were 
used as exclusion criteria: type 1 diabetes, requirements of cortico-
steroid treatment, positive clinical history of malignancy, chronic 
or acute renal failure, chronic liver disease, abuse of alcohol or any 
kind of drug, and hypothyroidism or endocrine diseases other than 
diabetes. The main anthropometric and clinical variables of the 
study population are described in Table 1.
Patient management before surgery and 
discharge
The preoperative evaluations included assessment by an endocrinolo-
gist, psychiatrist, pulmonologist, and anesthesiologist to identify and 
treat all comorbid medical conditions before the surgery according 
to standard guidelines. All patients were required to complete a pre-
operative low-calorie diet (800 kcal/d or less replacing all usual food 
intake) in order to decrease liver steatosis and mesenteric fat infiltra-
tion before bariatric surgery. The duration of this very low-calorie 
diet was adapted to the patient’s BMI, and an almost 5-point reduc-
tion in BMI was mandated for all patients with a preoperative BMI 
higher than 50 kg/m2. This diet was supplemented with a multivita-
min complex in order to provide the daily allowances of all essential 
nutrition requirements. Laparoscopic Roux-en-Y gastric bypass or 
sleeve gastrectomy was performed using a five-trocar approach in 
26 and 39 patients, respectively. During bariatric surgery, SAT and 
VAT biopsies were performed, quickly minced, frozen in liquid ni-
trogen, and stored at −80°C for further analysis. Demographic data 
(gender and age), BMI, waist circumference, and prior diagnosis of 
type 2 diabetes were also collected. Preoperative weight was defined 
as the weight on the day of surgery. Ideal body weight was estimated 
using the weight of the “large frame” from the corresponding height 
from the 1983 Metropolitan Life Insurance Company weight-height 
tables. The percentage of expected weight loss at month 12 (EWL12, 
in kilograms) was calculated by the following formula: (weight loss 
at month 12 × 100) ÷ (preoperative weight − ideal body weight). Type 
2 diabetes and impaired fasting glucose were defined according to 
the criteria recommended by the Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus (14). None of the patients 
with diabetes (24 patients) was being treated with insulin.
Animal experiment and diets
Three-week-old male CD-1 Swiss mice (initial weight, mean 22.1 g 
[SD 1.9]) obtained from Harlan Laboratories (Catalunya, Spain) were 
maintained at 23°C SD (2°C) under a 12 hour:12 hour light:dark cycle 
(lights on from 7:00 am to 7:00 pm). All mice were allowed unlimited 
access to an in-house-produced high-fat diet (59% of energy from fat) 
for 4 months. After that period of time, half of the animals were 
exposed to a normocaloric diet (25% of energy from fat) for 2 months, 
and the other half continued with the high-fat diet as a control group. 
Body weight and food and beverage intake were measured weekly 
throughout the study. After the 2 months of treatment with the nor-
mocaloric diet, subcutaneous glucose and insulin tolerance tests were 
performed. Then all animals were euthanized, and VAT was collected, 
frozen in liquid nitrogen, and stored at −80°C. All animal procedures 
followed the approved protocols from the Institutional Animal Care 
and Use Committee and by the Ethics Committee of the University of 
Lleida (Approval Number CEEA 18-01/12).
TABLE 1 Characteristics of study participants (N = 65)
Parameter Mean ± SD (range)
Age (y) 48 ± 10 (24-68)
Sex 25 male; 40 female
BMI (kg/m2) 44.0 ± 4.9 (36-59)
Type 2 diabetes mellitus (%) 37%
Hypertension (%) 66%
Dyslipidemia (%) 55%
Obstructive sleep apnea syndrome (%) 51%
Fasting glucose (mg/dL) 112 ± 43 (54-301)
HbA1c (%) 6.23 ± 1.34 (4.60-10.90)
LDL cholesterol (mg/dL) 48 ± 15 (20-100)
HDL cholesterol (mg/dL) 112 ± 30 (54-175)
Triglycerides (mg/dL) 189 ± 178 (59-1,141)
NEFA (mmol/L) 0.847 ± 0.398 
(0.242-2.514)
Type of surgery Bypass 26 cases;  
gastrectomy 39 cases
HbA1c, hemoglobin A1c.
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Subcutaneous glucose and insulin tolerance tests
Mice were fasted for 12 hours or 2 hours and then injected subcuta-
neously with glucose (2 g/kg body weight) or insulin (0.5 U/kg body 
weight; insulin solution from bovine pancreas, #I0516; Sigma-Aldrich, 
St. Louis, Missouri), respectively, with a rest period of 5 days between 
tests. Blood samples were taken every 20 minutes (0-120 minutes) from 
the tail vein, and blood glucose levels were determined with a porta-
ble glucometer (Accu-Chek Aviva 05911982002; Roche Diagnostics, 
Basel, Switzerland). The area under the curve was calculated as the 
sum of trapezoids in both tests.
Adipose tissue homogenization
Samples were homogenized in a buffer containing 20mM Tris (pH 8), 
150mM NaCl, 2 mM EDTA, 1% Triton X-100 (Sigma-Aldrich), 10% 
glycerol, 1μM butylated hydroxyl toluene, 10 μg/mL of aprotinin, 
1mM NaF, 1mM Na3VO4, and a protease inhibitor mix (80-6501-23; 
GE Healthcare, Chicago, Illinois) (1% volume per volume) with a 
Potter-Elvehjem device at 4°C. After samples were centrifuged (14,000 
rpm; 20 min; 4°C), the lower phase was collected for further analy-
sis. Protein concentrations were measured using the Bradford protein 
assay (BioRad Laboratories, München, Germany).
Analysis of protein oxidative modifications
Glutamic semialdehydes (GSA) and aminoadipic semialdehydes 
(AASA), glycoxidation (carboxyethyl-lysine [CEL] and carboxymeth-
yl-lysine [CML]), lipoxidation (malondialdehyde-lysine [MDAL]), and 
2-succinocystein (2SC) were determined by gas chromatography-mass 
spectrometry (GS-MS) as trifluoroacetic acid methyl esters derivatives 
in acid-hydrolyzed de-lipidated and reduced protein samples using an 
HP 6890 Series II gas chromatograph (Agilent, Barcelona, Spain) with a 
5975 Series MSD and a 7683 Series automatic injector with an Rtx-5MS 
Restek column (30  m × 0.25  mm × 0.25  μm). Quantification was per-
formed by internal and external standardization using standard curves 
constructed from mixtures of deuterated and nondeuterated standards. 
Analyses were carried out by selected ion-monitoring GC-MS. The 
ions used were as follows: lysine and [2H8]lysine mass to charge ratio 
[m/z] 180 and 187, respectively), 5-hydroxy-2-aminovaleric acid and 
[2H5]5-hydroxy-2-aminovaleric acid (stable derivatives of GSA; m/z 280 
and 285, respectively), 6-hydroxy-2-aminocaproic acid and [2H4]6-hydroxy- 
2-aminocaproic acid (stable derivatives of AASA; m/z 294 and 298, 
respectively), CML and [2H4]CML (m/z 392 and 396, respectively), CEL 
and [2H4]CEL (m/z 379 and 383, respectively), MDAL and d8-MDAL 
(m/z 474 and 482, respectively), and 2SC and d2-2SC (m/z 284 and 286, 
respectively). The amounts of product are expressed as the micromolar 
ratio of GSA, AASA, CML, CEL, MDAL, and 2SC per mol of lysine.
Mitochondrial DNA level quantification
Total DNA was extracted using Gentra Puregene Tissue Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. A 
TaqMan real-time polymerase chain reaction (PCR) was performed 
within the ABI PRISM 7300HT sequence detection system using the 
TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, 
California). To quantify mitochondrial DNA (mtDNA) content, 100 ng 
of total DNA was used, and cytochrome b (Hs05296867-s1, Custom 
TaqMan Gene Expression Assays; Applied Biosystems, Warrington, UK) 
was used as an mtDNA marker. Quantification of mtDNA was referred to 
nuclear DNA as determined by the amplification 18S (Hs03003631-g1, 
Custom TaqMan Gene Expression Assays) using the comparative 
(2−ΔCt) method, according to the manufacturer’s instructions.
Tissue antioxidant capacity
Adipose tissue antioxidant capacity was measured by the ferric reduc-
ing antioxidant power (FRAP) method. Briefly, 900 μL of the FRAP 
reagent, containing 2,4,6-tripyridyl-S-triazine, FeCl3, and acetate buf-
fer, was mixed with 90 μL of distilled water and 30 μL of the test 
sample or the blank (solvents used for homogenization). Maximum ab-
sorbance values taken at 595 nm were taken every 15 seconds at 37°C. 
The readings at 30 minutes were selected for calculations of FRAP 
values. Solutions of known trolox (238813; Sigma-Aldrich) concentra-
tion were used for antioxidant capacity equivalents.
Statistical analysis
Data are presented as mean (SD). Analysis of Gaussian distribution 
of all variables was performed by D’Agostino-Pearson omnibus nor-
mality test. The statistical significance comparison of variables with 
normal Gaussian distribution was calculated by paired t test, two-way 
ANOVA analysis with least significant difference as a post hoc test, 
or Pearson correlation analysis. Non-normal Gaussian distribution was 
analyzed by Wilcoxon matched-paired signed rank test, Kruskal-Wallis 
test with Dunn as a post hoc test, or Spearman correlation analysis. 
In both cases, P < 0.05 in all statistical tests employed was considered 
statistically significant. P values in correlation analyses were adjusted 
for multiple comparisons by false discovery rate method, and q-values 
for each correlation are indicated. The receiver operating characteris-
tic (ROC) curve was calculated considering volunteers with a lower 
response (EWL12 below 59% - lower 95% CI) and volunteers with 
a higher response (EWL12 above 68% - higher 95% CI). GraphPad 
Prism version 5.0 (GraphPad Software, San Diego, California) and 
MetaboAnalyst (version 3.0; https ://www.metab oanal yst.ca/faces/ 
home.xhtml ) were used for statistical analysis and graph plotting.
Results
The percentage weight loss observed at 12 months after the sur-
gery in this study was between 14% and 57% with respect to the 
initial body weight (95% CI: 28.9%-37.3%), with a coefficient of 
variation of 32.7%. The evolution of percentage of EWL at 1 to 12 
months is described in Supporting Information Figure S1A. No dif-
ferences were observed in EWL12 between the two types of sur-
geries (EWL12 for bypass 65.2  kg [14.6] and gastrectomy 62.1  kg 
[14.0]; P = 0.4853) or gender (EWL12 for males 65.2  kg [3.7] and 
females 62.3 kg [2.7]; P = 0.5549). Similarly, no differences in weight 
loss have been observed between the two types of surgeries by other 
authors (15). In relation to pathologies prior to the surgery, a lower 
percentage of EWL12 was observed among individuals with type 2 
diabetes mellitus (P = 0.0212), hypertension (P = 0.0044), and dyslip-
idemia (P = 0.0046) (Supporting Information Figure S1B-S1D), all 
components of metabolic syndrome.
Based on these results, other markers at the cellular level that could 
explain the difference in weight loss were evaluated. Among them, two 
protein oxidative modification markers, specifically CEL and 2SC, 
showed a directly proportional correlation with percentage of EWL12 
(Figure 1). Individuals with higher levels of CEL and 2SC prior to sur-
gery (both in SAT and VAT) showed greater weight loss. To rule out 
whether the increase in glycoxidation markers was related to the inci-
dence of diabetes, CEL and 2SC levels were evaluated according to 
the presence or absence of type 2 diabetes mellitus (Figure 2A-2B). 
Participants with type 2 diabetes mellitus showed reduced levels of CEL 
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Figure 1 Adipose tissue protein oxidative damage markers. (A) Correlation table of the values of protein oxidative biomarkers in SAT and VAT. Color of circles indicates 
the Spearman correlation coefficient, such that the red color describes a direct proportion correlation while the blue color inverse proportion. Size of circle denotes the 
significance of the correlation. The larger the size, the closer the P values are to 0. (B-E) Correlation between EWL12 and the preoperative values of CEL and 2SC in SAT 
and VAT. B slope = 10.4 ± 3.2 (r2 = 0.2212, P = 0.0025, and q = 0.0048); C slope = 6.8 ± 2.4 (r2 = 0.1775, P = 0.0084, and q = 0.0149); D slope = 85,094 ± 23,256 (r2 = 0.2711, 
P = 0.0008, and q = 0.0012); and E slope = 35,376 ± 17,575 (r2 = 0.1037, P = 0.0495, and q = 0.0495). Direct proportional correlation was observed between the levels of 
CEL and 2SC in SAT and CEL in VAT with EWL. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2 Differences in CEL and 2SC in SAT and VAT from participants with or without diabetes mellitus (DM) and ROC analysis for the use 
of SAT’s 2SC levels as a predictor of weight loss. (A,B) Volunteers without DM presented higher values of CEL and 2SC in SAT compared 
with the participants with DM (P = 0.0266 and P = 0.0316, respectively). (C) ROC curve for SAT’s levels of 2SC as a predictor of EWL12. 
(D) 2SC in SAT at lower and higher 95% CIs of volunteers’ EWL12. “*” denotes statistical differences between the selected parameters. 
[Colour figure can be viewed at wileyonlinelibrary.com]
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and 2SC in both SAT and VAT. The difference was significant between 
tissues and for the presence or absence of diabetes for 2SC (P = 0.0015 
and P = 0.0088, respectively) and for the presence or absence of diabe-
tes for CEL (P = 0.0162). The increase in CEL and 2SC levels could be 
attributed to the presurgery dietary treatment that all patients under-
went; however, the reduction in body weight was scarce, with an aver-
age of 7 kg of weight reduction.
To evaluate the performance of adipose tissue levels of 2SC and 
CEL as a predictor of weight-loss success, ROC analyses were per-
formed. Only the levels of 2SC in SAT showed an adequate sensitivity 
(Figure 2C-2D), in which values above 4.7 × 106 µmol/mol lysine (95% 
CI: 3.4 × 106 to 6.0 × 106) might be a good predictor of successful weight 
loss. 2SC and CEL levels in VAT and CEL levels in SAT showed lower 
sensitivity (ROC curve areas 0.6513, 0.6923, and 0.6974, respectively).
Differences in the levels of markers of oxidative modification between 
SAT and VAT were also observed. Higher levels of almost all pro-
tein oxidative biomarkers were observed in SAT compared with VAT 
(Table 2). In the same way, higher levels of antioxidant capacity, mea-
sured by the FRAP method, as well as higher mitochondrial density, 
were observed in VAT compared with SAT. Similarly, good correlation 
was found between SAT CEL levels and lipid metabolism by means 
of nonesterified fatty acid (NEFA) plasmatic levels (slope −252 [107]; 
r2 = 0.2702; P = 0.0325).
To verify this behavior in another model, the content of CEL was eval-
uated in the adipose tissue of mice with obesity subjected to weight- 
reduction treatments through a normocaloric diet for 2 months. The 
mean percentage weight loss observed was 9% (95% CI: 6.3%-11.6%). 
In the same way, as in humans, it was observed that lower body weight 
after dietary treatment was significantly associated with higher levels 
of CEL in adipose tissue (Figure 3A). Adipose tissue CEL levels in the 
control group (high-fat diet) were lower than observed in the weight-re-
duction group (P = 0.0378; mean [lower-upper 95% CI] 329 [296-363] 
and 377 [350-403] μmol of CEL/mol of lysine, respectively). Similarly, 
mice with a lower area under the curve after a subcutaneous glucose 
and insulin tolerance test (Supporting Information Figure S2), which 
suggests better glucose homeostasis, also showed higher levels of CEL 
in adipose tissue (Figure 3B-3C), suggesting that the capacity to reduce 
body weight and a greater capacity for glycemic control could be related 
to the glycolytic capacity of adipose tissue. To determine whether the 
changes in biomarkers of protein oxidative damage in adipose tissue 
could be related to oxidative stress status at the body level, a correla-
tion analysis was performed between several biomarkers of oxidative 
modifications in three key tissues of metabolism (liver, skeletal muscle, 
and adipose tissue) (Figure 3D). No correlation was observed between 
the levels of the different biomarkers analyzed between tissues. In fact, 
biomarkers of protein oxidative modification were clustered by tissue 
type rather than by type of oxidative modification. That is, the elevated 
levels of CEL and 2SC in adipose tissue were not translated to higher 
levels of these biomarkers in other tissues such as liver and skeletal 
muscle (P values of Pearson correlation analysis for CEL P = 0.995 and 
P = 0.139 for muscle and liver, respectively; and for 2SC P = 0.875 and 
P = 0.592 for muscle and liver, respectively), which may suggest that 
each tissue presents different levels of oxidative status.
Discussion
Bariatric surgery has been the preferred treatment for individuals with 
morbid obesity. However, the percentage weight loss can vary consid-
erably among individuals who undergo this type of surgery. Based on 
the results from this study, adipose tissue glycolytic capacity may be 
an important indicator of the individual’s ability to reduce body weight 
after bariatric surgery. Therefore, protein glycoxidation biomarkers 
like CEL and 2SC can also be used as biomarkers of glycolytic flux in 
adipose tissue as an indicator of metabolic activity. Others have recog-
nized that metabolism impacts or is impacted by virtually every other 
cellular process (16). And obesity-related cardiometabolic diseases are 
increasingly being recognized as disorders of metabolic inflexibility, 
in which nutrient overload and heightened substrate competition result 
in mitochondrial inflexibility, impaired fuel switching, and energy 
dysregulation (17), which will later result in a reduction in energy 
metabolic rate. Altogether, these could serve as predictors of the ability 
of individuals with obesity to respond to weight-reduction plans.
Figure 4 provides a scheme of the proposed mechanism by which 
higher levels of protein glycoxidation biomarkers may be related to 
insulin resistance and metabolic capacity. 2SC is a chemical modifica-
tion of proteins formed by the reaction of the Krebs cycle intermediate 
fumarate with cysteine residues in proteins (18). Increased succination 
of proteins is a direct result of increased fumarate concentration, as a 
potential consequence of high glucose disposal in adipose tissue. 
Increased protein succination formation during high-fat diets or type 
2 diabetes is a differential feature in adipose tissue compared with 
other organs such as skeletal muscle, liver, heart, lungs, and brain (19), 
suggesting that it could serve as a specific biomarker of adipose tissue 
glycolytic metabolism. CEL is considered an advanced glycation end 
product (AGE) formed during the reaction of methylglyoxal, a subproduct 
TABLE 2 Protein oxidation biomarkers, antioxidant capacity, and mitochondrial DNA in adipose tissue
Protein oxidation biomarker (μmol/mol of lysine) SAT VAT P value
CML 2.0 × 105 ± 1.0 × 105 1.2 × 105 ± 4.8 × 104 <0.0001
CEL 571 ± 388 256 ± 122 0.0023
MDAL- 2,051 ± 985 395 ± 241 0.0016
2SC 3.2 × 106 ± 2.8 × 106 1.7 × 106 ± 1.9 × 106 <0.0001
GSA 7.5 × 106 ± 4.3 × 106 6.0 × 106 ± 2.8 × 106 0.0001
AASA 1.8 × 105 ± 1.2 × 105 1.8 × 105 ± 1.0 × 105 0.9692
FRAP (μmol/g tissue) 1,333 ± 360 1,452 ± 282 0.0145
mtDNA/actin 85.9 ± 44.9 99.6 ± 61.5 0.0915
Data presented as mean ± SD. Paired t test performed to estimate individual differences within tissues.
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derived from the enzymatic activity of glyceraldehyde-3-phosphate and 
cellular proteins (20). In this context, as some authors have suggested 
elsewhere, both CEL and 2SC are proportionally derived from the rate 
of cell glycolytic capacity (18,21,22), and in both cases, their increased 
production may be favored by glucose uptake in adipose tissue through 
insulin stimulation.
The correlation between CEL and plasma NEFA could be explained 
in part by the interaction between lipid and carbohydrate metabolism. 
Carbohydrate metabolism intersects with triglyceride storage through 
the generation of glycerol-3-phosphate by way of dihydroxyacetone 
phosphate produced by glucose partially passing through glycolysis. 
Additionally, lactate is considered an autocrine molecule that 
mediates part of the insulin-dependent inhibition of lipolysis (13). 
Adipose tissue is an important source of lactate, and it converts more 
than 50% of the metabolized glucose to lactate, a process stimulated 
by insulin and glucose uptake (23). In this context, it was observed 
that the increase in lactate plasma concentrations, as a marker of 
glycolytic pathways, was accompanied by a decrease in NEFA plasma 
concentration (13). Similar findings were observed in this study, in 
which NEFA plasmatic levels were inversely correlated with CEL 
content in adipose tissue from individuals with diabetes. This feature 
may have important metabolic consequences because high circulating 
levels of NEFA are implicated with the ectopic accumulation of 
lipids in other tissues, translating the metabolic inflexibility to other 
tissues.
The lower CEL levels in adipose tissue in patients with diabetes might 
seem counterintuitive, based on high levels of circulating glycation 
products and the observed increase in adipose tissue protein carbonyla-
tion in individuals with obesity and lower insulin sensitivity (24,25). 
It is well known that circulating AGE correlates with hemoglobin A1c 
levels (26-28), with r values ranging between 0.26 and 0.65. In our 
cohort, no significant relationships were found between adipose tissue 
Figure 3 Correlation between CEL content in mice adipose tissue and postdietary treatment outcomes. (A-C) Inverse correlation was observed between CEL 
content and both final body weight and the area under the curve after a subcutaneous glucose tolerance and insulin test (slope −0.054 ± 0.017 [r2 = 0.1651] for 
body weight; slope −31.6 ± 15.5 [r2 = 0.2702, P = 0.0474, q = 0.0686] and slope −18.13 ± 8.18 [r2 = 0.0928, P = 0.0314, q = 0.0419] for the area under the curve for 
glucose and insulin tests, respectively). (D) Correlation and cluster analysis between different biomarkers of protein oxidative damage (2SC, GSA, CEL, CML, 
and MDAL) in adipose tissue, muscle, and liver. Red squares denote positive correlations and blue squares negative correlations. Letters beside initials of 
biomarkers correspond to the following: A, adipose tissue; L, liver; M, muscle. [Colour figure can be viewed at wileyonlinelibrary.com]
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levels of CEL or 2SC and hemoglobin A1c (P values for correlation in 
either subcutaneous or visceral depots ranged between 0.2 and 0.6), 
suggesting that tissue determinants of AGE accumulation could differ 
from those indicating circulating AGE values. The latter suggest that 
changes of adipose tissue CEL could depend on several factors besides 
glycemic control. Of note, other researchers have found no increased 
circulating AGE values in patients with insulin resistance, at least at 
the impaired fasting glucose stage (29). Consequently, it is possible to 
speculate that decreased CEL tissue levels in the human cohort could 
be due to decreased levels of insulin-driven glycolysis and/or increased 
protein turnover, both factors that are due to insulin resistance.
The results presented in this study are in agreement with previous 
studies regarding the differences in oxidation markers between VAT 
and SAT in that this study observed greater metabolic activity in VAT. 
For example, although the relationship between mtDNA and nuclear 
DNA is the same in both tissues, VAT (per milligram of tissue) was 
shown to be more metabolically active than SAT (8). Similarly, it was 
observed that VAT contained more mitochondria per milligram of 
tissue than SAT, and it was concluded that VAT was bioenergetically 
more active and more sensitive to mitochondrial substrate supply than 
SAT (7). Together with the results of the present study, these findings 
may suggest that metabolic capacity in SAT can be crucial as a deter-
minant of weight loss.
Some limitations can be raised, and additional confirmation of this 
behavior is necessary by other types of analysis like metabolism 
inflexibility assessment and energy expenditure after an insulin chal-
lenge (30) or physical activity (31). Additionally, all study partic-
ipants were subjected to a dietary intervention with a hypocaloric 
diet (800 kcal/d) prior to the collection of adipose samples. Because 
of this, it is not possible to determine whether the increase in the 
observed protein oxidative modification was due to the previous 
dietary treatment or was a special feature of individuals with obesity 
who present an adequate metabolic capacity. In this context, further 
studies are recommended to identify which adipose tissue proteins 
are modified and the plausible cellular and physiological changes 
induced by their oxidative modification.
Figure 4 Proposed mechanism of the observed effects. Prior to the surgery, participants underwent a weight-reduction plan. Patients with metabolic flexibility 
and/or insulin sensitivity will have the ability to uptake glucose and metabolize it. Increase in glycolytic pathways may induce higher levels of fumarate, which 
is highly reactive to protein-cysteine, and 2SC adducts may be formed. As a side effect of the increase in the glycolytic pathways, methylglyoxal may be 
formed from glyceraldehyde-3-P. Because of the reactivity of methylglyoxal, CEL adducts may be formed. Patients without metabolic flexibility and/or insulin 
sensitivity will have a reduced flux in the glycolytic pathways, which in turn will show lower levels of 2SC and CEL adducts. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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Conclusion
Based on the findings of this study, it is possible to conclude that 
protein glycoxidation content in SAT and VAT, such as CEL and 2SC 
adducts, may be useful biomarkers of adipose tissue metabolic capac-
ity and, together, may help to identify “good” and “bad” responders to 
bariatric surgery. O
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